Tony Fong is managing editor for 360Dx, GenomeWeb's news site on the in vitro diagnostics market.
The company anticipates total revenues of $3.9 billion for 2020, including $1 billion from its COVID-19-related business.
In announcing a national emergency on Friday, Trump paraded out executives from the private sector as the administration tries to increase testing capacity
The partners will use Namocell's single-cell dispensing tool and Takara's Smart-seq technology to isolate and characterize HepaTx's hepatocyte-like cells.
Centogene opened a Boston office in December and plans to open a lab there in a few months as it awaits an FDA decision on its clinical tool.
Winship's director of the cancer tissue and pathology shared resource said that some labs aren't leveraging molecular technologies due to reimbursement issues.
While molecular testing is now routine in cancer and women's health, for other disease areas, the technology may be overkill, Sundin said.
With recent and impending launches of POC MDx platforms, some industry observers believe the technology could replace some POC immunoassays in a few years.
The Singaporean molecular diagnostics firm, which went into judicial management in March, has new financial backing from a Chinese pharmaceutical firm.
Launched in April, the Japan Agency for Medical Research and Development is charged with streamlining that country's unwieldy funding process.
The firm will withdraw its planned IPO after being told that it would have to take a 30 to 40 percent discount to its valuation, its CEO said.